Foff Erin Pennock 4
4 · MapLight Therapeutics, Inc. · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
MapLight Therapeutics CMO Erin Foff Sells Shares
What Happened
Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics (MPLT), sold a total of 47,158 shares in a series of open-market transactions between July 15 and July 17, 2026, yielding approximately $1,734,490 in proceeds. Individual transactions reported include: 7,155 shares at $36.16 ($258,725), 7,845 shares at $37.04 ($290,579), 4,465 shares at $36.00 ($160,740), 8,972 shares at $36.99 ($331,874), an 18-share sale at $37.54 ($676), 9,163 shares at $36.46 ($334,083), 5,865 shares at $37.26 ($218,530), a 19-share sale at $37.96 ($721), and 3,656 shares at $37.90 ($138,562). All transactions are coded as sales (S).
Key Details
- Transaction dates: July 15–17, 2026; filing date: July 17, 2026 (Form 4 filed same day).
- Aggregate sold: 47,158 shares for ~$1,734,490.
- Shares owned after transaction: Not specified in the provided filing data.
- Notable footnotes: the filing states the trades were made pursuant to a Rule 10b5-1 trading plan adopted Dec 29, 2025; one small sale was a mandatory "sell to cover" to satisfy statutory tax withholding on vested RSUs; several prices are reported as weighted averages covering ranges of per‑share prices (full breakdown available from the issuer/SEC on request).
- Transaction type code: S = Sale; F4 corresponds to tax-withholding (sell-to-cover) treatment in the footnotes.
Context
Sales by executives can be routine (planned trading under 10b5-1 plans or to cover taxes) and do not necessarily signal a change in company outlook. The presence of a 10b5-1 plan indicates many of these sales were pre-arranged, and the "sell to cover" sale reflects a non‑discretionary tax withholding event. Retail investors should treat purchases as stronger indicators of insider confidence than routine, pre-planned sales.
Insider Transaction Report
- Sale
Voting Common Stock
[F1][F2]2026-07-15$36.16/sh−7,155$258,725→ 338,904 total - Sale
Voting Common Stock
[F1][F3]2026-07-15$37.04/sh−7,845$290,579→ 331,059 total - Sale
Voting Common Stock
[F4][F5]2026-07-15$36.00/sh−4,465$160,740→ 326,594 total - Sale
Voting Common Stock
[F4][F6]2026-07-15$36.99/sh−8,972$331,874→ 317,622 total - Sale
Voting Common Stock
[F4]2026-07-15$37.54/sh−18$676→ 317,604 total - Sale
Voting Common Stock
[F4][F7]2026-07-16$36.46/sh−9,163$334,083→ 308,441 total - Sale
Voting Common Stock
[F4][F8]2026-07-16$37.26/sh−5,865$218,530→ 302,576 total - Sale
Voting Common Stock
[F4]2026-07-16$37.96/sh−19$721→ 302,557 total - Sale
Voting Common Stock
[F4][F9]2026-07-17$37.90/sh−3,656$138,562→ 298,901 total
Footnotes (9)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.70 to $36.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.701 to $37.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.